Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Phone Reviews
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Phone Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / At least half of Indians have COVID-19 antibodies: Credit Suisse
India

At least half of Indians have COVID-19 antibodies: Credit Suisse

Ramya Patelkhana
Written by
Ramya Patelkhana
Mail
Last updated on Jun 09, 2021, 11:03 pm
At least half of Indians have COVID-19 antibodies: Credit Suisse
Credits:

Leading financial services company Credit Suisse revealed at least half of the Indian population, as per its estimates, would now have developed antibodies against COVID-19 caused by the novel coronavirus. Neelkanth Mishra, Co-head of Asia Pacific Strategy and India Equity Strategist, Credit Suisse, said many Indian districts would have moved beyond the herd immunity phase even for the highly infectious Delta variant. Here's more.

In this article
  • About 77 crore Indians would have already developed COVID-19 antibodies
  • Estimates based on hypotheses; national seroprevalence survey recommended: Mishra
  • Positive test ratios higher in second wave
  • Mishra explains how 77 crore Indians would have developed antibodies
  • It's estimated many districts would be well beyond herd immunity
  • A steep rebound of GDP in India likely: Mishra
Details

About 77 crore Indians would have already developed COVID-19 antibodies

Speaking to The Print, Mishra said as per Credit Suisse's estimates about 77 crore people in India would have already developed COVID-19 antibodies—a little more than half of India's population. This high seroprevalence of COVID-19 antibodies and the ongoing relaxation of lockdown and other restrictions across many states may even lead to a "steep rebound" of the gross domestic product (GDP) in the country.

Estimation

Estimates based on hypotheses; national seroprevalence survey recommended: Mishra

Estimates based on hypotheses; national seroprevalence survey recommended: Mishra
Credits:

Moreover, Mishra said these estimates are based only on hypotheses and not the real-time status. "We recommend a granular and nationwide seroprevalence study," he said. Credit Suisse's estimates are based on the Indian Council of Medical Research's third serological survey that showed by mid-December 2020, 21.4% of Indians were infected and the infection-to-case ratio was 28x—one crore cases and 28 crore people with antibodies.

Information

Positive test ratios higher in second wave

Mishra noted there were higher positive test ratios in the second COVID-19 wave compared to the first wave and hence ratio of those with antibodies in this wave would at least be the same as the first wave and "possibly even higher."

Conservative model

Mishra explains how 77 crore Indians would have developed antibodies

Mishra explains how 77 crore Indians would have developed antibodies
Credits:

Estimating the number of people with antibodies, Mishra said, "If, to be conservative, one model with 20x, we are at about 60 crore infections (28 crore in the first wave and 32 crore in the second wave) in addition to 17 crore people with at least one jab of the vaccine." So, about 77 crore people in the country would now have developed antibodies.

Explanation

It's estimated many districts would be well beyond herd immunity

Mishra said, "From this (estimated 77 crore with antibodies) you take out say 5 crore for double-counting—such as people infected twice or thrice or overlaps between those with infections and those with vaccination—and you still have around half the population with antibodies." "If you use 30x, many districts would be well beyond herd immunity even for the much more infectious Delta variant," he added.

On GDP

A steep rebound of GDP in India likely: Mishra

A steep rebound of GDP in India likely: Mishra

Mishra also spoke about the GDP, saying it should witness a significant improvement as lockdown restrictions are being lifted gradually—the rebound would be "steep." "If active cases continue to fall...steeply...relaxation of lockdowns is likely to be faster. While we need to be on the lookout for another surge...as activities resume, the likely high seroprevalence should reduce the risk of that occurrence," he said.

  • Credit Suisse
  • Coronavirus
  • COVID-19
  • Coronavirus Cases In India
  •  

Latest News

  • 2021 French Open: Djokovic reaches semis after beating Berrettini

    2021 French Open: Djokovic reaches semis after beating Berrettini

    Sports
  • NewsBytes Briefing: Apple keeps Android users in check, and more

    NewsBytes Briefing: Apple keeps Android users in check, and more

    Science
  • Unofficial bookings of the Yamaha FZ-X bike open in India

    Unofficial bookings of the Yamaha FZ-X bike open in India

    Auto
  • Realme C21Y, with Android 11 (Go edition), to debut soon

    Realme C21Y, with Android 11 (Go edition), to debut soon

    Science
  • 2022 Opel Grandland, with refreshed design and more features, unveiled

    2022 Opel Grandland, with refreshed design and more features, unveiled

    Auto

Features

  • 'Black fungus' infection: What is it, symptoms, and treatment

    'Black fungus' infection: What is it, symptoms, and treatment

    India
  • India to have 8 vaccines by year-end. Which are they?

    India to have 8 vaccines by year-end. Which are they?

    India
  • DRDO's anti-coronavirus drug: Its efficacy, price, and more queries answered

    DRDO's anti-coronavirus drug: Its efficacy, price, and more queries answered

    India

Related News

  • Ramdev calls allopathy 'stupid science', Medical Association demands his prosecution

    Ramdev calls allopathy 'stupid science', Medical Association demands his prosecution

    India
  • India may buy 50mn Pfizer COVID-19 vaccine doses: Details here

    India may buy 50mn Pfizer COVID-19 vaccine doses: Details here

    India
  • India's COVID-19 vaccination drive, registration, priority beneficiaries: Everything to know

    India's COVID-19 vaccination drive, registration, priority beneficiaries: Everything to know

    India
  • 7.4 crore Indians exposed to coronavirus till August: ICMR serosurvey

    7.4 crore Indians exposed to coronavirus till August: ICMR serosurvey

    India
Trending Topics
Vaccine
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Karnataka West Bengal Bihar Virat Kohli Rohit Sharma Haryana
Narendra Modi Tamil Nadu Gujarat Yogi Adityanath YouTube Hollywood News Uttar Pradesh WhatsApp Kerala Netflix
Bollywood News Mamata Banerjee Sonia Gandhi Rahul Gandhi Hotstar Shah Rukh Khan Chelsea FC Vaccine OPPO Amazon Prime
Manchester United Salman Khan Amitabh Bachchan Vivo Mobiles Manchester City La Liga Samsung Mobiles Xiaomi Mobiles OnePlus Mobiles Honda Cars
Hyundai Cars Premier League Team India Latest Automobile News
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021